Clinical Trials on Unknown Primary Tumors in Hungary

Total 809 results

GlaxoSmithKline

Completed

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Cancer

Australia, Spain, United States, Germany, Poland, Italy, Canada, Ireland, Hungary, Russian Federation, Netherlands, France
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States, Belgium, Spain, Hungary, Italy, Canada, United Kingdom, France
Incyte Corporation

Recruiting

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Advanced Solid Tumor

Georgia, Greece, Turkey, Brazil, Romania, Serbia, South Africa, New Zealand, China, Hungary, Malaysia, Singapore
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Renal Impairment Study

Renal Impairment

Czech Republic, Hungary
European Association of Urology Research Foundation

Completed

Epidemiology and Outcomes of Gram Negative Urosepsis (SERPENS)

Urosepsis

Norway, Hungary, Italy, North Macedonia, Poland, Portugal, Turkey
Bristol-Myers Squibb

Completed

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Melanoma

Germany, Italy, Sweden, United Kingdom, Belgium, Netherlands, Spain, Finland, Austria, Ireland, Poland, Portugal, Russian Federation, Switzerland, Czechia, Greece, Hungary, Luxembourg, Norway, Romania
IBSA Institut Biochimique SA

Completed

Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients

Infertility

Switzerland, Denmark, France, Hungary, United Kingdom
PregLem SA

Completed

PGL2001 Proof of Concept Study in Symptomatic Endometriosis (AMBER)

Endometriosis

Hungary, Romania, Poland
Novartis Pharmaceuticals

Completed

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

Hypertension

United States, Belgium, France, Germany, Hungary, India, Italy, Poland, Turkey
Hoffmann-La Roche

Completed

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

Urinary Tract Infections

United States, Serbia, Hungary, Latvia, Poland
Actelion

Completed

Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United Kingdom, Austria, Belgium, France, Germany, Hungary, Italy, Poland
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
Galapagos NV

Terminated

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) (GLIDER)

Primary Sjögren Syndrome

Germany, Greece, Poland, Hungary, Ukraine
Fresenius Medical Care Deutschland GmbH
Institut Dr. Schauerte GmbH (IDS)

Completed

Comparison of Clinical Performance and Hemocompatibility of Dialyzers Applied During Post-dilution Online Hemodiafiltration (eMPORAIII)

Renal Failure | End Stage Renal Disease

Germany, Czechia, Hungary
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Pain | Tumor

Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, Spain, Sweden
Bristol-Myers Squibb
Medarex

Completed

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Melanoma

United States, Brazil, France, Italy, South Africa, United Kingdom, Argentina, Australia, Canada, Ireland, Israel, Russian Federation, Spain, Belgium, Germany, Portugal, Chile, Austria, Poland, Netherlands, Ukraine, Czech Republic, ... and more
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Novartis Pharmaceuticals

Completed

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)

Neuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung Origin

United States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Agenus Inc.

Completed

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Malignant Melanoma

United States, Australia, Poland, Ukraine, United Kingdom, Russian Federation, Hungary, Italy, Sweden
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
European Organisation for Research and Treatment...

Completed

Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Penile Cancer

France, United Kingdom, Poland, Belgium, Netherlands, Hungary
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
Technical University of Munich
Novalung GmbH, Heilbronn, Germany; Studiensekretariat Intensivmedizin; II....

Unknown

Extracorporeal Lung Assist Device in Acute Lung Impairment (EXODUS)

Acute Respiratory Distress Syndrome

Austria, Germany, Hungary, United Kingdom
Novartis Pharmaceuticals

Completed

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

Melanoma

United States, United Kingdom, Austria, Belgium, Hungary, Canada, Netherlands, Argentina, Australia, Brazil, Czechia, Denmark, France, Germany, Israel, Italy, Norway, Poland, Russian Federation, Spain, Switzerland, Taiwan, Korea, Republic... and more
Minster Research Ltd

Completed

Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

Migraine Without Aura | Migraine With Aura

United Kingdom, Denmark, Hungary, South Africa
RECORDATI GROUP

Completed

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Prostate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRAS

Belgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Kedrion S.p.A.

Recruiting

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) (KIDCARES10)

Primary Immunodeficiency Disease

Italy, United States, Portugal, Hungary, Russian Federation, Slovakia
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Hendrik Streeck
Janssen, LP

Completed

Prospective Observational Cohort HIV & STI Study in Europe

HIV Infections | Sexual Behavior | HIV-1-infection | Risk Reduction

France, Hungary, Spain, Poland, Italy
Erasmus Medical Center
The European Association for Cardio-Thoracic Surgery

Unknown

Serial Multiparametric Evaluation of Right Ventricular Function After Left Ventricular Assist Device Implantation (EuroEchoVAD)

Right Heart Failure

Netherlands, Germany, Hungary, Italy, Kazakhstan, Turkey, United Kingdom
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary, Argentina
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Acute Kidney Injury Due to Sepsis

Hungary, Belgium, Germany, France, Spain
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Melanoma

Argentina, United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Gilead Sciences

Completed

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Rectal Cancer | Colon Cancer | Colorectal Carcinoma | Colorectal Tumor

United States, Sweden, Germany, Hungary, Switzerland
Octapharma

Recruiting

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency

United States, Germany, Italy, Poland, Slovakia, Ukraine, Hungary
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Melanoma

United States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
argenx
Iqvia Pty Ltd

Completed

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) (rho)

Primary Sjögren's Syndrome

Belgium, Poland, Hungary, Netherlands
Aptabio Therapeutics, Inc.

Completed

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Diabetes Mellitus, Type 2 | Diabetic Nephropathies | Nephropathy, Diabetic

Bulgaria, Czechia, Hungary, Serbia
Octapharma

Completed

Study of Octanorm Subcutaneous IG in Patients With PID

Primary Immune Deficiency Disorder

United States, Canada, Czechia, Hungary, Poland, Russian Federation, Slovakia
Bayer

Completed

REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy

Erectile Dysfunction

Poland, China, Croatia, France, Germany, Hungary, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, South Africa, Spain, Sweden, Thailand

Clinical Trials on Unknown Primary Tumors in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations